Regeneron Pharmaceuticals, Inc. (REGN) Stake Lessened by NEXT Financial Group Inc
NEXT Financial Group Inc decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 40.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 495 shares of the biopharmaceutical company’s stock after selling 340 shares during the quarter. NEXT Financial Group Inc’s holdings in Regeneron Pharmaceuticals were worth $219,000 at the end of the most recent quarter.
Other large investors have also made changes to their positions in the company. Fieldpoint Private Securities LLC bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $130,000. Sterling Investment Advisors Ltd. raised its holdings in Regeneron Pharmaceuticals by 11.2% in the 2nd quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock valued at $137,000 after acquiring an additional 28 shares in the last quarter. FNY Partners Fund LP raised its holdings in Regeneron Pharmaceuticals by 200.0% in the 2nd quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 200 shares in the last quarter. IFP Advisors Inc raised its holdings in Regeneron Pharmaceuticals by 33.2% in the 2nd quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 96 shares in the last quarter. Finally, Virtu KCG Holdings LLC acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $206,000. Hedge funds and other institutional investors own 66.51% of the company’s stock.
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) traded up $1.57 during mid-day trading on Wednesday, hitting $386.02. 58,814 shares of the stock traded hands, compared to its average volume of 900,146. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.07 and a current ratio of 3.63. Regeneron Pharmaceuticals, Inc. has a 12 month low of $340.09 and a 12 month high of $543.55. The stock has a market cap of $41,387.65, a price-to-earnings ratio of 33.35, a P/E/G ratio of 1.51 and a beta of 1.56.
A number of equities analysts have recently issued reports on REGN shares. Leerink Swann reissued a “positive” rating and issued a $552.00 target price (down from $580.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 15th. Robert W. Baird raised Regeneron Pharmaceuticals from an “underperform” rating to a “neutral” rating in a report on Friday, November 3rd. Piper Jaffray Companies reissued an “overweight” rating and issued a $557.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 1st. Zacks Investment Research cut Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Finally, Guggenheim reaffirmed a “buy” rating and set a $540.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, October 23rd. Two investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $475.34.
In other news, SVP Robert E. Landry sold 427 shares of the firm’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $493.43, for a total transaction of $210,694.61. Following the sale, the senior vice president now owns 9,099 shares in the company, valued at approximately $4,489,719.57. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Charles A. Baker sold 2,000 shares of the firm’s stock in a transaction on Friday, September 29th. The shares were sold at an average price of $450.00, for a total transaction of $900,000.00. Following the sale, the director now owns 11,000 shares in the company, valued at approximately $4,950,000. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 4,779 shares of company stock valued at $2,248,467. 10.80% of the stock is owned by insiders.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.